Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Latigo Biotherapeutics Inc (LTGO) had Consolidated Net Income/Loss of $-109.17M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-109.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-109.17M |
|
|
Consolidated Net Income/Loss |
$-109.17M |
-- |
|
-- |
|
-- |
|
0.84M |
|
0.84M |
|
$-129.23 |
|
$-129.23 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|